Calithera Biosciences, Inc. CALA

CALA Company Overview

Calithera Biosciences, Inc. was a clinical-stage biotechnology company focused on discovering and developing small-molecule therapeutics targeting tumor metabolism and immunology pathways for cancer treatment. The company primarily operated within the biotechnology and oncology drug development industries, with research efforts centered on glutamine metabolism, cellular stress response pathways, and immuno-oncology mechanisms. Its lead development programs included telaglenastat, a glutaminase inhibitor evaluated in multiple oncology indications, alongside earlier-stage metabolic pathway candidates intended to enhance anti-tumor immune activity.

The company’s business model relied primarily on research and development activities funded through public equity financing, strategic collaborations, and licensing arrangements rather than commercial product revenue. Calithera was founded in 2010 and headquartered in South San Francisco, California. Public filings and corporate disclosures indicate the company significantly reduced operations after late-stage clinical setbacks involving telaglenastat. Available public records show that Calithera subsequently pursued strategic alternatives and corporate restructuring activities. Data regarding any continuing independent operating business after these restructuring efforts is inconclusive based on available public sources.